Payment overview · 2025
General Payments
$998.22
35 reported records · 14 companies
Healthcare provider profile · identity verified
Mark H Bowles, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · WICHITA, KS · NPI 1902884224
Verified facts
What the public records show
CMS Open Payments records show Mark H Bowles, MD received $998.22 in general payments during 2025 across 35 reported records.
Janssen Biotech, Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zenpep by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $229.78 | 23.0% | 11 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $201.40 | 20.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $143.92 | 14.4% | 3 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $94.92 | 9.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $81.67 | 8.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.65 | 4.6% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $44.51 | 4.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.95 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.24 | 3.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.75 | 2.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.25 | 1.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $15.54 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.38 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.26 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $914.22 | 34 |
| Education | $84.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $229.78 | 11 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $201.40 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $143.92 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $94.92 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $81.67 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $45.65 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $44.51 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $42.34 | 3 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $42.34 | 3 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $42.34 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.24 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
201 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 405 | 111 |
| Ezetimibe | Ezetimibe | 322 | 75 |
| Losartan Potassium | Losartan Potassium | 302 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 295 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 229 | 56 |
| Famotidine | Famotidine | 210 | 47 |
| Eliquis | Apixaban | 201 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 192 | 39 |
| Sucralfate | Sucralfate | 182 | 53 |
| Furosemide | Furosemide | 152 | 35 |
| Carvedilol | Carvedilol | 149 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 44 |
| Potassium Chloride | Potassium Chloride | 135 | 27 |
| Lisinopril | Lisinopril | 125 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 32 |
| Xarelto | Rivaroxaban | 100 | 19 |
| Omeprazole | Omeprazole | 88 | 18 |
| Nifedipine Er | Nifedipine | 83 | 11 |
| Sotalol | Sotalol Hcl | 75 | 17 |
| Repatha Sureclick | Evolocumab | 73 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 70 | 24 |
| Lactulose | Lactulose | 70 | 25 |
| Flecainide Acetate | Flecainide Acetate | 69 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 13 |
| Simvastatin | Simvastatin | 67 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 18 |
| Nitroglycerin | Nitroglycerin | 65 | 38 |
| Spironolactone | Spironolactone | 65 | 19 |
| Warfarin Sodium | Warfarin Sodium | 63 | 18 |
| Linzess | Linaclotide | 59 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 19 |
| Misoprostol | Misoprostol | 49 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | 15 |
| Clonidine | Clonidine | 44 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 43 | 12 |
| Cilostazol | Cilostazol | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Erythromycin | Erythromycin Base | 39 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Mesalamine | Mesalamine | 33 | suppressed |
| Creon | Lipase/Protease/Amylase | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Mexiletine Hcl | Mexiletine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Gabapentin | Gabapentin | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Mercaptopurine | Mercaptopurine | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Budesonide Dr | Budesonide | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $998.22 · 35 records | Janssen Biotech, Inc. | ABRYSVO, Assure WCD, COMIRNATY, Cologuard Collection Kit, DUPIXENT, ENTYVIO, Kerendia, LEQVIO, LifeVest, PREVNAR 20, SIMPONI, SIMPONI ARIA, STELARA, STRENSIQ, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TREMFYA, Wegovy, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Zenpep play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error